PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells

Toxicology Letters

Volumn 220, Issue 2, 2013, Pages 150-156

  Wang, Feng Ze ^a   Peng Jiao, ^a   Yang, Na Na ^a   Chuang Yuan, ^a   Zhao, Ya Li ^a   Liu, Qiang Qiang ^a   Fei, Hong Rong ^a   Zhang, Ji Guo ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Apoptosis; Cell cycle; PF 04691502; PI3K Akt

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PF 04691502; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASES; CELL GROWTH PROCESSES; CELL MOVEMENT; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINTS; HEP G2 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRIDONES; PYRIMIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879000445     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.04.018     Document Type: Article

References (32)

1. Ahluwalia A., Tarnawski A.S. Critical role of hypoxia sensor-HIF-1α in VEGF gene activation Implications for angiogenesis and tissue injury healing. Current Medicinal Chemistry 2012, 19:90-97.
2. Arora D.K., Mohammed A.M., Kowluru A. Nifedipine prevents etoposide-induced caspase-3 activation, prenyl transferase degradation and loss in cell viability in pancreatic β-cells. Apoptosis 2012, 18:1-8.
3. Auzenne E.J., Klostergaard J., Mandal P.K., Liao W.S., Lu Z., Gao F., Bast R.C., Robertson F.M., McMurray J.S. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. Journal of Experimental Therapeutics and Oncology 2012, 10:155-162.
4. Bibollet-Bahena O., Almazan G. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways. Journal of Neurochemistry 2009, 109:1440-1451.
5. Boreddy S.R., Sahu R.P., Srivastava S.K. Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3. PLoS ONE 2012, 6:e25799. 10.1371/journal.pone.0025799.
6. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. Journal of Clinical Oncology 2010, 28:1075-1083.
7. Estaquier J., Vallette F., Vayssiere J.L., Mignotte B. The mitochondrial pathways of apoptosis. Advances in Experimental Medicine and Biology 2012, 942:157-183.
8. Fei H.R., Cui L.Y., Zhang Z.R., Zhao Y., Wang F.Z. Caudatin inhibits carcinomic human alveolar basal epithelial cell growth and angiogenesis through modulating GSK3β/β-catenin pathway. Journal of Cellular Biochemistry 2012, 113:3403-3410.
9. Fu J., Chen Y., Cao J., Luo T., Qian Y.W., Yang W., Ren Y.B., Su B., Cao G.W., Yang Y., Yan Y.Q., Shen F., Wu M.C., Feng G.S., Wang H.Y. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways. Hepatology 2011, 53:181-192.
10. Hers I., Vincent E.E., Tavaré J.M. Akt signalling in health and disease. Cellular Signalling 2011, 23:1515-1527.
11. Jakubowiak A.J., Richardson P.G., Zimmerman T., Alsina M., Kaufman J.L., Kandarpa M., Kraftson S., Ross C.W., Harvey C., Hideshima T., Sportelli P., Poradosu E., Gardner L., Giusti K., Anderson K.C. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. British Journal of Haematology 2012, 158:472-480.
12. Jiang B.H., Liu L.Z. AKT signaling in regulating angiogenesis. Current Cancer Drug Targets 2008, 8:19-26.
13. Karar J., Cerniglia G.J., Lindsten T., Koumenis C., Maity A. Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia. Cancer Biology and Therapy 2012, 13:1102-1111.
14. Kurtz J.E., Ray-Coquard I. PI3 kinase inhibitors in the clinic: an update. Anticancer Research 2012, 32:2463-2470.
15. Lee H., Jung K.H., Jeong Y., Hong S., Hong S.S. HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. Cancer Letters 2013, 328:152-159.
16. Maluccio M., Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA: A Cancer Journal for Clinicians 2012, 62:394-399.
17. Marone R., Cmiljanovic V., Giese B., Wymann M.P. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochimica et Biophysica Acta 2008, 1784:159-185.
18. Martelli A.M., Evangelisti C., Chappell W., Abrams S.L., Bäsecke J., Stivala F., Donia M., Fagone P., Nicoletti F., Libra M., Ruvolo V., Ruvolo P., Kempf C.R., Steelman L.S., McCubrey J.A. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011, 25:1064-1079.
19. Maximilian L.W., Maike A.L., Markus R. The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. Experimental Cell Research 2012, 318:1213-1220.
20. Mucaj V., Shay J.E., Simon M.C. Effects of hypoxia and HIFs on cancer metabolism. International Journal of Hematology 2012, 95:464-470.
21. Park J.H., Lee J.Y., Shin D.H., Jang K.S., Kim H.J., Kong G. Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1α mediated by the PTEN/PI3K/Akt pathway. Oncogene 2011, 30:4578-4589.
22. Psyrri A., Arkadopoulos N., Vassilakopoulou M., Smyrniotis V., Dimitriadis G. Pathways and targets in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2012, 12:1347-1357.
23. Sadeghi N., Gerber D.E. Targeting the PI3K pathway for cancer therapy. Future Medicinal Chemistry 2012, 4:1153-1169.
24. Sheppard K., Kinross K.M., Solomon B., Pearson R.B., Phillips W.A. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Critical Reviews in Oncogenesis 2012, 7:69-95.
25. Shiojima I., Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes and Development 2006, 20:3347-3365.
26. Wang F.Z., Fei H.R., Li X.Q., Shi R., Wang de C. Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells. Molecular and Cellular Biochemistry 2012, 368:1-8.
27. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nature Medicine 2011, 17:1359-1370.
28. Xu Y., Zuo Y., Zhang H., Kang X., Yue F., Yi Z., Liu M., Yeh E.T., Chen G., Cheng J. Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF expression and angiogenesis. Journal of Biological Chemistry 2010, 285:36682-36688.
29. Yuan J., Mehta P.P., Yin M.J., Sun S., Zou A., Chen J., Rafidi K., Feng Z., Nickel J., Engebretsen J., Hallin J., Blasina A., Zhang E., Nguyen L., Sun M., Vogt P.K., McHarg A., Cheng H., Christensen J.G., Kan J.L., Bagrodia S. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Molecular Cancer Therapy 2011, 10:2189-2199.
30. Zhang J., Lu A., Li L., Yue J., Lu Y. p16 modulates VEGF expression via its interaction with HIF-1alpha in breast cancer cells. Cancer Investigation 2010, 28:588-597.
31. Zhou Q., Lui V.W., Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncology 2011, 7:1149-1167.
32. Zhou S.L., Dai Z., Zhou Z.J., Wang X.Y., Yang G.H., Wang Z., Huang X.W., Fan J., Zhou J. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology 2012, 56:2242-2254.